Hosted on MSN6h
HC Wainwright & Co. Initiates Coverage of CRISPR Therapeutics (CRSP) with Buy Recommendation
Fintel reports that on February 3, 2025, HC Wainwright & Co. initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...
Crispr Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Crispr Therapeutics (CRSP) with a Buy rating and $65 price target The firm says ...
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...
Blackstone: My Bet On This $1 Trillion Asset Manager Continues To Pay Dividends
Learn about Blackstone's $1 trillion in AUM, diversified investment strategies, strong balance sheet, and future growth ...
Zacks.com on MSN13h
Is First Trust SMID Cap Rising Dividend Achievers ETF (SDVY) a Strong ETF Right Now?
A smart beta exchange traded fund, the First Trust SMID Cap Rising Dividend Achievers ETF (SDVY) debuted on 11/01/2017, and offers broad exposure to the Style Box - Mid Cap Value category of the ...
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
China Evergrande's EV unit says struggling to attract investors amid liquidity crisis
"The tough conditions under which the new energy vehicle in Mainland China is operating has certainly not facilitated this ...